|1||Not yet recruiting||
A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ
Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances
|3||Not yet recruiting||
A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer
|5||Not yet recruiting||
PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
|6||Not yet recruiting||
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
|7||Not yet recruiting||
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
† Study has passed its completion date and status has not been verified in more than two years.